Do analysts prefer VTEX or ZSQR?

VTEX currently has a consensus price target of $4.69, suggesting a potential upside of 33.36%. Given VTEX's stronger consensus rating and higher possible upside, research analysts plainly believe VTEX is more favorable than Coeptis Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score VTEX 0 Sell rating(s) 6 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33 Coeptis Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings and valuation, VTEX or ZSQR?

VTEX has higher revenue and earnings than Coeptis Therapeutics. Coeptis Therapeutics is trading at a lower price-to-earnings ratio than VTEX, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio VTEX $240.52M 2.49 $20.01M $0.16 21.97 Coeptis Therapeutics $1.36M 121.20 -$11.92M -$1.63 N/A

Is VTEX or ZSQR more profitable?

VTEX has a net margin of 11.98% compared to Coeptis Therapeutics' net margin of -773.72%. VTEX's return on equity of 12.98% beat Coeptis Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets VTEX 11.98% 12.98% 8.76% Coeptis Therapeutics -773.72% -49.45% -46.88%

Do analysts recommend OOMA or ZSQR?

Ooma currently has a consensus price target of $25.00, suggesting a potential upside of 9.87%. Given Ooma's stronger consensus rating and higher possible upside, equities research analysts clearly believe Ooma is more favorable than Coeptis Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ooma 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83 Coeptis Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, OOMA or ZSQR?

Ooma has higher revenue and earnings than Coeptis Therapeutics. Coeptis Therapeutics is trading at a lower price-to-earnings ratio than Ooma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ooma $273.60M 2.29 $6.46M $0.38 59.88 Coeptis Therapeutics $1.36M 121.20 -$11.92M -$1.63 N/A

Is OOMA or ZSQR more profitable?

Ooma has a net margin of 3.57% compared to Coeptis Therapeutics' net margin of -773.72%. Ooma's return on equity of 23.89% beat Coeptis Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Ooma 3.57% 23.89% 10.97% Coeptis Therapeutics -773.72% -49.45% -46.88%

Do analysts rate ZSQR or HKD?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Coeptis Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 AMTD Digital 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, ZSQR or HKD?

AMTD Digital has higher revenue and earnings than Coeptis Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Coeptis Therapeutics $1.36M 121.20 -$11.92M -$1.63 N/A AMTD Digital $136.10M 3.95 $54.71M N/A N/A

Do analysts rate ZSQR or SWMR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Coeptis Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Swarmer 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate ZSQR or MFI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Coeptis Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 mF International 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings & valuation, ZSQR or MFI?

mF International has higher revenue and earnings than Coeptis Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Coeptis Therapeutics $1.36M 121.20 -$11.92M -$1.63 N/A mF International $4.35M 108.02 $10.12M N/A N/A

Coeptis Therapeutics (ZSQR) Competitors

$3.10 +0.15 (+5.08%)

As of 12:03 PM Eastern

Compare

ZSQR vs. VTEX, OOMA, HKD, SWMR, and MFI

Should you buy Coeptis Therapeutics stock or one of its competitors? Coeptis Therapeutics's main competitors and comparable companies include VTEX (VTEX), Ooma (OOMA), AMTD Digital (HKD), Swarmer (SWMR), and mF International (MFI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "application software" industry.

How does Coeptis Therapeutics compare to VTEX?

VTEX (NYSE:VTEX) and Coeptis Therapeutics (NASDAQ:ZSQR) are both small-cap technology companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, analyst recommendations, institutional ownership, dividends, valuation and profitability.

VTEX currently has a consensus price target of $4.69, suggesting a potential upside of 33.36%. Given VTEX's stronger consensus rating and higher possible upside, research analysts plainly believe VTEX is more favorable than Coeptis Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VTEX	0 Sell rating(s)	6 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Coeptis Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

63.7% of VTEX shares are held by institutional investors. Comparatively, 13.9% of Coeptis Therapeutics shares are held by institutional investors. 40.9% of VTEX shares are held by company insiders. Comparatively, 24.3% of Coeptis Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

VTEX has a net margin of 11.98% compared to Coeptis Therapeutics' net margin of -773.72%. VTEX's return on equity of 12.98% beat Coeptis Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
VTEX	11.98%	12.98%	8.76%
Coeptis Therapeutics	-773.72%	-49.45%	-46.88%

In the previous week, VTEX had 1 more articles in the media than Coeptis Therapeutics. MarketBeat recorded 1 mentions for VTEX and 0 mentions for Coeptis Therapeutics. VTEX's average media sentiment score of 0.00 equaled Coeptis Therapeutics'average media sentiment score.

Company	Overall Sentiment
VTEX	Neutral
Coeptis Therapeutics	Neutral

VTEX has higher revenue and earnings than Coeptis Therapeutics. Coeptis Therapeutics is trading at a lower price-to-earnings ratio than VTEX, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VTEX	$240.52M	2.49	$20.01M	$0.16	21.97
Coeptis Therapeutics	$1.36M	121.20	-$11.92M	-$1.63	N/A

VTEX has a beta of 0.99, indicating that its stock price is 1% less volatile than the broader market. Comparatively, Coeptis Therapeutics has a beta of -0.25, indicating that its stock price is 125% less volatile than the broader market.

Summary

VTEX beats Coeptis Therapeutics on 14 of the 15 factors compared between the two stocks.

How does Coeptis Therapeutics compare to Ooma?

Ooma (NYSE:OOMA) and Coeptis Therapeutics (NASDAQ:ZSQR) are both small-cap technology companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk, analyst recommendations and media sentiment.

Ooma has a beta of 1.2, meaning that its stock price is 20% more volatile than the broader market. Comparatively, Coeptis Therapeutics has a beta of -0.25, meaning that its stock price is 125% less volatile than the broader market.

Ooma has a net margin of 3.57% compared to Coeptis Therapeutics' net margin of -773.72%. Ooma's return on equity of 23.89% beat Coeptis Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ooma	3.57%	23.89%	10.97%
Coeptis Therapeutics	-773.72%	-49.45%	-46.88%

80.4% of Ooma shares are held by institutional investors. Comparatively, 13.9% of Coeptis Therapeutics shares are held by institutional investors. 9.9% of Ooma shares are held by insiders. Comparatively, 24.3% of Coeptis Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Ooma had 36 more articles in the media than Coeptis Therapeutics. MarketBeat recorded 36 mentions for Ooma and 0 mentions for Coeptis Therapeutics. Ooma's average media sentiment score of 0.71 beat Coeptis Therapeutics' score of 0.00 indicating that Ooma is being referred to more favorably in the media.

Company	Overall Sentiment
Ooma	Positive
Coeptis Therapeutics	Neutral

Ooma has higher revenue and earnings than Coeptis Therapeutics. Coeptis Therapeutics is trading at a lower price-to-earnings ratio than Ooma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ooma	$273.60M	2.29	$6.46M	$0.38	59.88
Coeptis Therapeutics	$1.36M	121.20	-$11.92M	-$1.63	N/A

Ooma currently has a consensus price target of $25.00, suggesting a potential upside of 9.87%. Given Ooma's stronger consensus rating and higher possible upside, equities research analysts clearly believe Ooma is more favorable than Coeptis Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ooma	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
Coeptis Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Ooma beats Coeptis Therapeutics on 14 of the 16 factors compared between the two stocks.

How does Coeptis Therapeutics compare to AMTD Digital?

Coeptis Therapeutics (NASDAQ:ZSQR) and AMTD Digital (NYSE:HKD) are both small-cap technology companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, media sentiment, risk, dividends and valuation.

AMTD Digital has a net margin of 0.00% compared to Coeptis Therapeutics' net margin of -773.72%. AMTD Digital's return on equity of 0.00% beat Coeptis Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coeptis Therapeutics	-773.72%	-49.45%	-46.88%
AMTD Digital	N/A	N/A	N/A

13.9% of Coeptis Therapeutics shares are held by institutional investors. Comparatively, 5.8% of AMTD Digital shares are held by institutional investors. 24.3% of Coeptis Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

AMTD Digital has higher revenue and earnings than Coeptis Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coeptis Therapeutics	$1.36M	121.20	-$11.92M	-$1.63	N/A
AMTD Digital	$136.10M	3.95	$54.71M	N/A	N/A

Coeptis Therapeutics has a beta of -0.25, indicating that its stock price is 125% less volatile than the broader market. Comparatively, AMTD Digital has a beta of 1.98, indicating that its stock price is 98% more volatile than the broader market.

In the previous week, Coeptis Therapeutics' average media sentiment score of 0.00 equaled AMTD Digital'saverage media sentiment score.

Company	Overall Sentiment
Coeptis Therapeutics	Neutral
AMTD Digital	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coeptis Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
AMTD Digital	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

AMTD Digital beats Coeptis Therapeutics on 6 of the 9 factors compared between the two stocks.

How does Coeptis Therapeutics compare to Swarmer?

Coeptis Therapeutics (NASDAQ:ZSQR) and Swarmer (NASDAQ:SWMR) are both small-cap technology companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coeptis Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Swarmer	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Swarmer had 2 more articles in the media than Coeptis Therapeutics. MarketBeat recorded 2 mentions for Swarmer and 0 mentions for Coeptis Therapeutics. Swarmer's average media sentiment score of 0.84 beat Coeptis Therapeutics' score of 0.00 indicating that Swarmer is being referred to more favorably in the news media.

Company	Overall Sentiment
Coeptis Therapeutics	Neutral
Swarmer	Positive

Swarmer has lower revenue, but higher earnings than Coeptis Therapeutics. Swarmer is trading at a lower price-to-earnings ratio than Coeptis Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coeptis Therapeutics	$1.36M	121.20	-$11.92M	-$1.63	N/A
Swarmer	$310K	1,733.35	-$8.53M	-$0.73	N/A

Swarmer has a net margin of 0.00% compared to Coeptis Therapeutics' net margin of -773.72%. Swarmer's return on equity of 0.00% beat Coeptis Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coeptis Therapeutics	-773.72%	-49.45%	-46.88%
Swarmer	N/A	N/A	N/A

13.9% of Coeptis Therapeutics shares are held by institutional investors. 24.3% of Coeptis Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Swarmer beats Coeptis Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Coeptis Therapeutics compare to mF International?

Coeptis Therapeutics (NASDAQ:ZSQR) and mF International (NASDAQ:MFI) are both small-cap technology companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, valuation, risk, media sentiment and analyst recommendations.

mF International has higher revenue and earnings than Coeptis Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coeptis Therapeutics	$1.36M	121.20	-$11.92M	-$1.63	N/A
mF International	$4.35M	108.02	$10.12M	N/A	N/A

mF International has a net margin of 0.00% compared to Coeptis Therapeutics' net margin of -773.72%. mF International's return on equity of 0.00% beat Coeptis Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coeptis Therapeutics	-773.72%	-49.45%	-46.88%
mF International	N/A	N/A	N/A

Coeptis Therapeutics has a beta of -0.25, indicating that its share price is 125% less volatile than the broader market. Comparatively, mF International has a beta of 7.04, indicating that its share price is 604% more volatile than the broader market.

13.9% of Coeptis Therapeutics shares are held by institutional investors. 24.3% of Coeptis Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coeptis Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
mF International	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Coeptis Therapeutics' average media sentiment score of 0.00 equaled mF International'saverage media sentiment score.

Company	Overall Sentiment
Coeptis Therapeutics	Neutral
mF International	Neutral

Summary

mF International beats Coeptis Therapeutics on 6 of the 9 factors compared between the two stocks.

Get Coeptis Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZSQR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZSQR vs. The Competition

Export

Metric	Coeptis Therapeutics	Software Industry	Technology Sector	NASDAQ Exchange
Market Cap	$164.83M	$15.55B	$30.10B	$12.90B
Dividend Yield	N/A	3.42%	2.73%	9.14%
P/E Ratio	-1.91	138.28	76.24	25.42
Price / Sales	121.20	1,288.95	592.73	93.88
Price / Cash	N/A	43.12	46.84	35.62
Price / Book	1.18	8.43	7.82	6.44
Net Income	-$11.92M	$434.48M	$703.05M	$358.18M
7 Day Performance	6.87%	-0.51%	1.09%	1.10%
1 Month Performance	-23.02%	-0.41%	-1.71%	-0.41%
1 Year Performance	-75.98%	3.52%	186.50%	13.98%

Coeptis Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count
ZSQR Coeptis Therapeutics	0.1326 of 5 stars	$3.11 +5.4%	N/A	-76.0%	$164.83M	$1.36M	N/A	2
VTEX VTEX	4.6652 of 5 stars	$3.62 +0.1%	$4.69 +29.7%	-11.4%	$615.46M	$240.52M	22.60	1,139
OOMA Ooma	3.4339 of 5 stars	$22.51 +2.9%	$25.00 +11.1%	+84.8%	$601.70M	$273.60M	59.24	1,420
HKD AMTD Digital	0.4825 of 5 stars	$1.69 +0.9%	N/A	+6.5%	$526.73M	$136.10M	N/A	50
SWMR Swarmer	0.6302 of 5 stars	$31.80 -1.2%	N/A	N/A	$513.17M	$310K	N/A	62

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ZSQR) was last updated on 9/8/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Coeptis Therapeutics (ZSQR) Competitors

ZSQR vs. VTEX, OOMA, HKD, SWMR, and MFI

How does Coeptis Therapeutics compare to VTEX?

Summary

How does Coeptis Therapeutics compare to Ooma?

Summary

How does Coeptis Therapeutics compare to AMTD Digital?

Summary

How does Coeptis Therapeutics compare to Swarmer?

Summary

How does Coeptis Therapeutics compare to mF International?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZSQR vs. The Competition

Coeptis Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Coeptis Therapeutics (ZSQR) Competitors

ZSQR vs. VTEX, OOMA, HKD, SWMR, and MFI

How does Coeptis Therapeutics compare to VTEX?

Do analysts prefer VTEX or ZSQR?

Do insiders & institutionals hold more shares of VTEX or ZSQR?

Is VTEX or ZSQR more profitable?

Does the media refer more to VTEX or ZSQR?

Which has higher earnings and valuation, VTEX or ZSQR?

Which has more risk & volatility, VTEX or ZSQR?

Summary

How does Coeptis Therapeutics compare to Ooma?

Which has more risk and volatility, OOMA or ZSQR?

Is OOMA or ZSQR more profitable?

Do insiders and institutionals have more ownership in OOMA or ZSQR?

Does the media prefer OOMA or ZSQR?

Which has better earnings & valuation, OOMA or ZSQR?

Do analysts recommend OOMA or ZSQR?

Summary

How does Coeptis Therapeutics compare to AMTD Digital?

Is ZSQR or HKD more profitable?

Do institutionals & insiders have more ownership in ZSQR or HKD?

Which has better earnings and valuation, ZSQR or HKD?

Which has more risk & volatility, ZSQR or HKD?

Does the media refer more to ZSQR or HKD?

Do analysts rate ZSQR or HKD?

Summary

How does Coeptis Therapeutics compare to Swarmer?

Do analysts rate ZSQR or SWMR?

Does the media refer more to ZSQR or SWMR?

Which has higher valuation & earnings, ZSQR or SWMR?

Is ZSQR or SWMR more profitable?

Do institutionals and insiders hold more shares of ZSQR or SWMR?

Summary

How does Coeptis Therapeutics compare to mF International?

Which has higher earnings & valuation, ZSQR or MFI?

Is ZSQR or MFI more profitable?

Which has more risk & volatility, ZSQR or MFI?

Do institutionals & insiders hold more shares of ZSQR or MFI?

Do analysts rate ZSQR or MFI?

Does the media prefer ZSQR or MFI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZSQR vs. The Competition

Coeptis Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools